Brief: Hcw Biologics Delivers A Major Update For Its T-Cell Engager Program Revealing Mechanism Of Action
27/04/2026 13:33
April 27 (Reuters) - HCW Biologics Inc HCWB.O: HCW BIOLOGICS DELIVERS A MAJOR UPDATE FOR ITS T-CELL ENGAGER PROGRAM REVEALING MECHANISM OF ACTION AND VALIDATING TISSUE FACTOR AS TARGET FOR TREATMENT OF SOLID TUMORS Source text: ID:nGNX2WfGQM Further company coverage: HCWB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hcw Biologics
See all newsBrief: HCW Biologics Proposed Resale Of Up To 5.69 Million Shares Of Common Stock
Brief: HCW Biologics To Regain Full Rights For Two Commercial-Ready Reagents From Wugen
Brief: HCW Biologics Prices Private Placement Of 2.8 Mln Units At $1.405 Per Unit
NASDAQ RESUMED AT 09:59 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:54 AM